{"url_path":"/sec/vtr/8-k/2026-05-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ** **    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/740260/0001104659-26-062795-index.html","accession_number":"0001104659-26-062795","cik":"0000740260","ticker":"VTR","issuer_name":"Ventas, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/740260/0001104659-26-062795-index.html","primary_entity_key":"0000740260","primary_entity_name":"Ventas, Inc."},"word_count":189,"has_tables":true,"body_markdown":"**Item 5.02.** **    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn May 12, 2026, in connection with his previously\ndisclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement\nwith Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge\nHealthcare Services, Inc. (the “Separation Agreement”), pursuant to which Mr. Bulgarelli will receive a payment\nequal to the prorated portion of his bonus under the Company’s annual incentive plan for 2026 based on target performance through\nthe effective date of his retirement (the “Prorated 2026 Bonus”). The Prorated 2026 Bonus is in consideration for, and contingent\nupon, among other things, Mr. Bulgarelli’s agreement to a standard release of claims and continued compliance with his restrictive\ncovenants.\n\n \n\nThe foregoing is a summary description of certain\nterms of the Separation Agreement and is qualified in its entirety by the full text of the Separation Agreement, a copy of which will\nbe filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026."}